{"organizations": [], "uuid": "f7fed05164b38ceb4d7a4961a7db0a591214cf69", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-idera-pharmaceuticals-reports-q4-l/brief-idera-pharmaceuticals-reports-q4-loss-per-share-0-08-idUSASB0C964", "country": "US", "domain_rank": 408, "title": "BRIEF-Idera Pharmaceuticals Reports Q4 Loss Per Share $0.08", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-07T14:34:00.000+02:00", "replies_count": 0, "uuid": "f7fed05164b38ceb4d7a4961a7db0a591214cf69"}, "author": "", "url": "https://www.reuters.com/article/brief-idera-pharmaceuticals-reports-q4-l/brief-idera-pharmaceuticals-reports-q4-loss-per-share-0-08-idUSASB0C964", "ord_in_thread": 0, "title": "BRIEF-Idera Pharmaceuticals Reports Q4 Loss Per Share $0.08", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-idera pharmaceuticals reports", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "idera pharmaceuticals", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "idera pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7, 2018 / 12:35 PM / Updated 10 minutes ago BRIEF-Idera Pharmaceuticals Reports Q4 Loss Per Share $0.08 Reuters Staff March 7 (Reuters) - Idera Pharmaceuticals Inc: * IDERA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE * Q4 LOSS PER SHARE $0.08 * IDERA PHARMACEUTICALS -AS OF DEC 31, 2017, OUR CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $112.6 MILLION COMPARED TO $109.0 MILLION AS OF DEC 31, 2016 * DEVELOPMENT DECISION FOR IDRA-008 EXPECTED DURING Q2 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-07T14:34:00.000+02:00", "crawled": "2018-03-07T14:48:47.027+02:00", "highlightTitle": ""}